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Abstract
Measures of dopamine-regulating proteins in somatodendritic regions are often used only as static indicators of neuron
viability, overlooking the possible impact of somatodendritic dopamine (DA) signaling on behavior and the potential
autonomy of DA regulation between somatodendritic and terminal field compartments. DA reuptake capacity is less in
somatodendritic regions, possibly placing a greater burden on de novo DA biosynthesis within this compartment to
maintain DA signaling. Therefore, regulation of tyrosine hydroxylase (TH) activity may be particularly critical for
somatodendritic DA signaling. Phosphorylation of TH at ser31 or ser40 can increase activity, but their impact on L-DOPA
biosynthesis in vivo is unknown. Thus, determining their relationship with L-DOPA tissue content could reveal a mechanism
by which DA signaling is normally maintained. In Brown-Norway Fischer 344 F1 hybrid rats, we quantified TH
phosphorylation versus L-DOPA accumulation. After inhibition of aromatic acid decarboxylase, L-DOPA tissue content per
recovered TH protein was greatest in NAc, matched by differences in ser31, but not ser40, phosphorylation. The L-DOPA per
catecholamine and DA turnover ratios were significantly greater in SN and VTA, suggesting greater reliance on de novo DA
biosynthesis therein. These compartmental differences reflected an overall autonomy of DA regulation, as seen by
decreased DA content in SN and VTA, but not in striatum or NAc, following short-term DA biosynthesis inhibition from local
infusion of the TH inhibitor a-methyl-p-tyrosine, as well as in the long-term process of aging. Such data suggest ser31
phosphorylation plays a significant role in regulating TH activity in vivo, particularly in somatodendritic regions, which may
have a greater reliance on de novo DA biosynthesis. Thus, to the extent that somatodendritic DA release affects behavior, TH
regulation in the midbrain may be critical for DA bioavailability to influence behavior.
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Introduction
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in
catecholamine biosynthesis [1,2]. The discovery that cAMP-
dependent protein kinase activated TH [3] launched research to
identify TH-phosphorylating protein kinases and phosphoryla-
tion sites; these were later characterized to be ser8, ser19, ser31,
and ser40, with ser40 being the PKA-phosphorylation site [4].
Later, ser31 was found to be phosphorylated by ERK [5].
Considerable evidence indicates that ser40 phosphorylation
increases L-DOPA biosynthesis [6–8], but the extent of its role
in brain is unknown. Despite this, inferences that ser40
phosphorylation affects TH activity or dopamine (DA) tissue
content in vivo abound in the literature. Two factors, however,
challenge the concept that ser40 phosphorylation plays a singular
role in regulating TH. First, while depolarizing stimuli increase
striatal ser19, ser31, and ser40 phosphorylation in vivo [9],
increased L-DOPA biosynthesis can occur without involvement
of ser40 under depolarizing conditions in situ [10,11]. Second,
given that basal ser40 phosphorylation stoichiometry in cate-
cholaminergic cells [8,11] and in brain [12–14] are comparable,
basal levels in brain may be below the threshold of ser40
phosphorylation necessary to increase L-DOPA biosynthesis, as
indicated in catecholaminergic cells [11].
Direct involvement of increased ser19 phosphorylation in L-
DOPA biosynthesis is not likely [15,16], leaving the prospect that
ser31 phosphorylation alone could be a critical phosphorylation
site for L-DOPA biosynthesis regulation in vivo. In support of this
concept, ser31 phosphorylation co-varies with DA tissue content in
vivo [14]. Therefore, in neuronal compartments where de novo DA
biosynthesis may be comparatively more critical to maintain
normal DA bioavailability, ser31 phosphorylation could have
considerable impact on DA regulation and, consequently, upon
DA-influenced behaviors. In fact, together both ser31 phosphor-
ylation status and TH protein content in the substantia nigra (SN)
have significant correlation to locomotor activity [14]. Interest-
ingly, ser31 TH phosphorylation, like DA tissue content, is
significantly less in somatodendritic regions than terminal field
regions of both the nigrostriatal and mesoaccumbens pathways
[12–14]. Still, there is an even greater disparity between these
compartments when it comes to DA reuptake capacity, which is
considerably less in somatodendritic regions [17–22]. The rate of
DA uptake is ,200-fold less in the SN compared to striatum [21].
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expression, which plays a major role in determining striatal DA
tissue content [23] and is ,3–10-fold less in somatodendritic
regions when normalized to TH protein [24]. Because DA
reuptake capacity is comparatively much less in somatodendritic
regions, TH activity, as influenced by site-specific phosphoryla-
tion, may play a greater role in maintaining DA bioavailability
therein. However, the extent to which ser31 or ser40 phosphor-
ylation contributes to DA tissue content in vivo is still an open
question, because either phosphorylation site can affect L-DOPA
biosynthesis and because DA tissue content is influenced by both
DAT and TH function [4,11,23,25].
The basal differences in TH phosphorylation and DA reuptake
between somatodendritic and terminal field regions imply that
regulation of DA bioavailability may be autonomous between
these compartments. We investigated this potential autonomy in
three approaches: by examining TH phosphorylation versus L-
DOPA and DA tissue content in CNS tissues, by determining how
local TH inhibition affected DA tissue content using an in vivo
pharmacological approach, and by assessing the impact of aging
on TH and DA tissue content. We provide evidence that in
somatodendritic compartments, DA tissue content may have
greater dependence on de novo biosynthesis and that ser31 TH
phosphorylation likely plays a major role in the regulation thereof.
The results also indicate that the regulation of DA biosynthesis and
metabolism is distinct and autonomous between the neuronal
compartments, an observation that has critical implications for the
modeling of DA-influenced behaviors.
Methods
Animals
Male Sprague-Dawley rats, ages 8–12 months, were purchased
from Harlan and used in the AMPT-infusion component of the
study. Male Brown-Norway Fischer 344 F1 hybrid rats (BNF) of 6,
18, and 24 months old were obtained from NIA and given food
and water ad libitum for at least seven days prior to tissue collection.
Male BNF rats of 12 months old were purchased from Harlan and
were used in the L-DOPA vs. TH phosphorylation component of
the study. Additional BNF rats (,6 months old) were used along
with Sprague-Dawley rats in the striatal AMPT infusion
experiments. These strains were selected because the BNF rat is
a proven model for aging and the Sprague-Dawley is a commonly
used strain. All procedures were approved by the LSUHSC
Institutional Animal Care and Use Committee under approval
number P-09-055 and carried out in accordance with the NIH
‘‘Principles of laboratory animal care’’ (NIH publication no. 85-
23).
Administration of NSD-1015 for L-DOPA and TH
phosphorylation determination
BNF rats of 12 months old were given a 50 mg/kg i.p. injection
of the aromatic amino acid decarboxylase (AADC) inhibitor NSD-
1015 (3-hydroxybenzylhydrazine dihydrochloride, Sigma, $98%
(HPLC), cat # 54880) dissolved in 0.9% saline. One hour later,
striatum, nucleus accumbens, SN, and VTA were dissected from
ice-cold chilled brain, as previously described [12,14]. The tissues
were processed for analysis of L-DOPA, DA, DOPAC, and
norepinephrine (NE) by the inclusion of an L-DOPA standard in
the HPLC buffer. Of note, L-DOPA could not be detected in
tissues without prior administration of NSD-1015. L-DOPA is
included in the sample buffer in detectable range via the HPLC
method employed for quantitative determination in sample.
Local AMPT infusion
Alpha-methyl-p-tyrosine (AMPT) methyl ester hydrochloride
(Sigma, $98% (TLC), cat # M3281) was dissolved in Krebs buffer
to a concentration of 0.92 mM and infused into the midbrain of
anesthetized rats at coordinates relative to Bregma (targeting the
SN (25.7 AP, 2.5 ML, 8.5 DV)) in a volume of 3 ml to deliver
1.38 nmoles of AMPT. Vehicle was infused in the contralateral
SN to serve as an inherently matched control, meaning that
baseline DA levels in each test subject (following vehicle-infusion)
were used to quantify AMPT effects. At 90 min after infusion, the
striatum, nucleus accumbens, SN, and VTA were dissected from
ice-cold chilled brain, as previously described [12,14]. This
quantity of AMPT was effective to significantly reduce DA tissue
content in both SN and striatum. Additional AMPT infusions in
striatum were also conducted to reduce DA tissue content,
delivering 7.0 nmoles AMPT in a volume of 4 ml. Dye infusion
studies using these volumes verified coverage of ,2.5 mm in the
rostral-caudal axis, and ,2 mm in the medial-lateral and dorsal-
ventral dimensions.
Tissue processing for HPLC and protein analysis
Dissected brain tissues were kept frozen at 270uC until
sonicated in ice-cold 0.1 M HClO4-EDTA buffer. Aliquots from
these protein-precipitated supernatants were analyzed for DA,
DOPAC, L-DOPA, and/or NE tissue content by HPLC [26].
Determination of DA is calculated based upon percent recovery of
the internal standard (N-methyl-dopamine, 20 ng/mL) in each
sample, the peak height ratios obtained for both DA and N-
methyl-dopamine in a standard and in the sample, and the
fraction of the aliquot analyzed by HPLC representing the total
volume of the sonicated tissue. This same method is used to
calculate L-DOPA, DOPAC, and NE. The acid buffer treatment
for HPLC analysis causes precipitation of the protein content in
the sample. The remaining buffer was archived and the protein
pellet was sonicated in 1% SDS with 5 mM Tris buffer (pH 8.3)
and 1 mM EDTA for determination of total protein, TH protein,
and site-specific TH phosphorylation. This methodology matches
L-DOPA and DA tissue content with the total recovered TH
protein and TH phosphorylation in each sample, as previously
reported [14,27] and since replicated in other laboratories [28].
Determination of TH protein and phosphorylation
Protein quantities were determined by BCA method. Protein
concentration in each aliquot was determined and multiplied by
the total volume of SDS to determine the entire protein quantity
(as mg) recovered in each sample. Total protein content is used to
normalize DA tissue content and TH protein from each sample.
For TH protein and TH phosphorylation determination, samples
are prepared in reducing (dithiothreitol used as reducing agent)
sample buffer containing SDS and are subjected to SDS gel
electrophoresis on 10% gels and transferred to nitrocellulose.
Protein loads are verified by Ponceau S stain and blots are put into
polyvinylpyrrolidone-based Tris buffer for at least 2 hr prior to
antibody exposure. For each blot immunolabeling experiment,
after treatment with primary and secondary antibody (for signal
enhancement), the detection method uses I
125-protein A (high-
specific activity). The blots are exposed to Kodak film to reveal
immunoreactive areas, which are excised and counted for gamma
radioactivity. In the case of quantification of the TH protein, the
value is expressed as cpm per ug total protein loaded [11–14,27].
In-house standards are used which interpolate sample immuno-
reactivity to anti-TH versus a standard curve of known quantities
of TH [11,12,14].
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blot using affinity-purified primary antibodies developed to the
specific phosphorylation site. We have our own affinity-purified
ser31 phosphorylation primary (21
st Century Biochemicals).
Antibodies specific for phosphorylated ser19 and ser40 were
purchased from Phosphosolutions (Aurora, CO). The ser31
primary antibody was previously validated for phosphorylation-
state specificity [14]. Calibrated phosphorylation site-specific in
house standards are used to quantify phosphorylation stoichiom-
etry levels and sample results are normalized to TH protein
content to determine the phosphorylation stoichiometry at each
phosphorylation site. Assays for TH protein and site-specific
phosphorylation are conducted within the dynamic working range
of each antibody, as defined by the standard curve.
Statistics
There are five major results presented with each using a specific
statistical approach. Determination of the differences between the
four DA regions (striatum, substantia nigra, nucleus accumbens,
and ventral tegmental area) with regard to endogenous L-DOPA
tissue content, ratio of L-DOPA per catecholamine, DA tissue
content, ratio of DOPAC per DA, TH protein, and TH
phosphorylation used a Repeated measures ANOVA followed
by Bonferroni’s Multiple Comparison Test. Pearson correlational
analysis was run on comparisons of L-DOPA per TH vs. TH
phosphorylation stoichiometries and ser19 TH phosphorylation
stoichiometry vs. ser31 and ser40 TH phosphorylation stoichiom-
etries. To determine if DA/TH in each of the four regions was
significantly different from the phosphorylation stoichiometries,
comparing str vs. SN, str vs. NAc, str vs. VTA, SN vs. NAc, SN vs.
VTA, and NAc vs. VTA, we used a Repeated Measures ANOVA
followed by Dunnett’s Multiple Comparison Test. Determination
of statistical significance in the AMPT-related work used a paired
Student’s t-test, comparing pmols DA per mg protein in the
AMPT-infused hemisphere versus pmols DA per mg protein in the
matched contralateral vehicle-infused hemisphere. For assessment
of aging-related effects on DA and TH measures, we assumed
normal distribution and used Repeated Measures ANOVA,
ranking the values obtained in each age group from highest to
lowest, followed by Bonferroni’s Multiple Comparison Test to
determine if significant differences existed between the age groups.
Results
In vivo relationship of L-DOPA accumulation and TH
phosphorylation
Quantifying L-DOPA in dopaminergic brain regions is the most
germane approach to determine TH activity since both DAT and
VMAT2 also regulate DA bioavailability in vivo. However, L-
DOPA is converted so efficiently into DA that L-DOPA is not
detectable in CNS tissue unless aromatic amino acid decarbox-
ylase (AADC) is inhibited. We verified linearity of L-DOPA
detection in dopaminergic tissue using the HPLC analysis
described in test rats that were given the AADC inhibitor NSD-
1015. To compare L-DOPA to TH phosphorylation profiles, we
then administered NSD-1015 (50 mg/kg i.p.) to 12-month old
BNF rats one hour prior to dissection of dopaminergic brain
regions. Total L-DOPA recovery (per protein) was greatest in
terminal field compartments, being highest in the NAc
(298612 pmols L-DOPA per mg protein) followed by the striatum
(26964 pmols L-DOPA per mg protein). Somatodendritic
compartments had comparatively less, being least in SN
(4063 pmols L-DOPA per mg protein) and then the VTA
(17269 pmols L-DOPA per mg protein) (Fig. 1A). The recovery
of TH (per protein) was greatest in the striatum (Fig. 1B). Notably,
despite relatively equal TH recovery in SN (87610 ng TH per mg
protein) and NAc (9668 ng TH per mg protein), significantly
greater L-DOPA was recovered from the NAc compared to the
SN (Fig. 1A).
To further examine differences in basal TH activity and how
site-specific phosphorylation affected L-DOPA content, we
normalized L-DOPA to TH content (Fig. 2A), providing a direct
comparison of product to enzyme levels. The ratio of L-DOPA per
TH was significantly greater in the NAc compared to any other
region examined (Fig. 2A), with no differences in this ratio among
SN, VTA, and striatum. The only region for which ser19 TH
Figure 1. Recovery of L-DOPA and TH from dopaminergic
tissues following i.p. NSD-1015 infusion. Recovery of L-DOPA and
TH from dopaminergic brain regions dissected one hour after 50 mg/kg
i.p. administration of NSD-1015 to BNF rat (n=4). A. pmols L-DOPA per
mg protein in dissected DA neuropil. L-DOPA per protein was
significantly different in each of the four regions being greatest in
the NAc (298612) followed by the striatum (26964), the VTA (17269),
and the SN (4063). Repeated measures ANOVA, p,0.0001, F=396.0,
post-hoc: (***str vs. SN, t=27.7, p,0.001; *str vs. NAc, t=3.49, p,0.05;
***str vs. VTA, t=11.8, p,0.001; ***SN vs. NAc, t=31.2, p,0.001; ***SN
vs. VTA, t=15.9, p,0.001; ***NAc vs. VTA, t=15.3, p,0.001). B. ng TH
per mg protein in dissected DA neuropil. TH per protein was
significantly greater in the striatum (635637) than the remaining three
regions, while TH per protein was also greater in the VTA (260647) than
in either the SN (87610) or the NAc (9668) which were not significantly
different from one another. Repeated measures ANOVA, p,0.0001,
F=97.5, post-hoc: (***str vs. SN, t=14.9, p,0.001; ***str vs. NAc, t=14.7,
p,0.001; ***str vs. VTA, t=10.2, p,0.001; SN vs. NAc, t=0.23, ns; **SN
vs. VTA, t=4.71, p,0.01; **NAc vs. VTA, t=4.48, p,0.01).
doi:10.1371/journal.pone.0029867.g001
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in the NAc was the SN (Fig. 2B), where ser19 phosphorylation
stoichiometry was greater in SN. Similar to L-DOPA per TH
(Fig. 2A), phosphorylation at ser31 in the NAc was significantly
greater than the other three regions examined (Fig. 2C). Both
terminal field regions also had greater ser31 phosphorylation than
their cognate somatodendritic regions. Like ser19 phosphoryla-
tion, phosphorylation at ser40 in the NAc was only significantly
different compared to that in SN, with higher phosphorylation
seen in the SN (Fig. 2D).
We emphasize that these observations were made during
inhibition of L-DOPA conversion to DA by the AADC inhibitor
NSD-1015. Thus, the inhibition of DA formation in the neuropil
may have influenced the TH phosphorylation observed in each
region. For example, ser40 phosphorylation in the SN was over
0.10, which exceeds previous observations [12–14].
Figure 2. Relationship of L-DOPA accumulation to tyrosine hydroxylase phosphorylation in vivo. Comparisons of L-DOPA per TH and TH
phosphorylation stoichiometries between dopaminergic brain regions dissected one hour after 50 mg/kg i.p. administration of NSD-1015 to BNF rat
(n=4). A. pmols L-DOPA per ng TH in dissected DA neuropil. There was significantly greater L-DOPA per TH in NAc (3.1860.34) compared to
all other regions (Striatum, 0.4360.02; SN, 0.5060.11; VTA 0.7160.10). Repeated measures ANOVA, p,0.0001,F=48.7, post-hoc: (str vs. SN, t=0.27,
ns; ***str vs. NAc, t=10.3, p,0.001; str vs. VTA, t=1.06, ns; ***SN vs. NAc, t=10.0, p,0.001; SN vs. VTA, t=0.79, ns; ***NAc v. VTA, t=9.21, p,0.001).
B. ser19 phosphorylation stoichiombetry; TH phosphorylation stoichiometry at ser19 was significantly higher in the SN than all other regions
except the VTA (ANOVA, p=0.0005, F=16.5, post-hoc (str v. SN, t=6.52, p,0.001; str v. VTA, t=3.56, p,0.05; **SN v. NAc, t=5.31, p,0.01)). Only
significant differences between the NAc and the other brain regions are depicted in the figure in order to better draw a comparison to the significant
differences in L-DOPA per TH as observed in Fig 2A. Stoichiometry values were str=0.09860.005, SN=0.34060.024, NAc=0.14360.010,
VTA=0.23060.047. C. ser31 phosphorylation stoichiometry; NAc had significantly greater ser31 phosphorylation stoichiometry than any other
region, SN had significantly less than all other regions, and terminal field regions had significantly greater ser31 phosphorylation stoichiometry than
their cognate somatodendritic regions (ANOVA, p,0.0001, F=71.3, post-hoc (str v. SN, t=9.90, p,0.001; *str v. NAc, t=4.11, p,0.05; str v. VTA,
t=4.00, p,0.05; ***SN v. NAc, t=14.0, p,0.001; SN v. VTA, t=5.89, p,0.01; ***NAc v. VTA, t=8.12 p,0.001)). Only significant differences between
the NAc and the other brain regions are depicted in the figure in order to better draw a comparison to the significant differences in L-DOPA per TH as
observed in Fig 2A. Stoichiometry values were str=0.30560.025, SN=0.08360.011, NAc=0.39860.024, VTA=0.21560.025. D. ser40
phosphorylation stoichiometry; TH phosphorylation stoichiometry at ser40 was significantly higher in SN than in all other regions (ANOVA,
p=0.0005, F=16.9, post-hoc (str v. SN, t=4.01, p,0.05; **SN v. NAc, t=5.19, p,0.01; SN v. VTA, t=6.82, p,0.001)). Only significant differences
between the NAc and the other brain regions are depicted in the figure in order to better draw a comparison to the significant differences in L-DOPA
per TH as observed in Fig 2A. Stoichiometry values were str=0.08560.005, SN=0.11860.008, NAc=0.07560.006, VTA=0.06260.004.
doi:10.1371/journal.pone.0029867.g002
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catecholamine biosynthesis
Although L-DOPA recovery from the somatodendritic regions
was much less than the terminal fields (Fig. 1A), in comparison to
the amount of catecholamines (DA and norepinephrine (NE))
recovered from these same tissues, the somatodendritic regions had
significantly greater pmols L-DOPA per pmol catecholamine
(Fig. 3A). In fact, the ratio of L-DOPA to catecholamines was
highest in the VTA (1.1360.120) followed by the SN (0.7560.044),
which were 2.7 and 4.5-fold greater, respectively, than their
corresponding terminal field compartments in NAc and striatum.
This indicates that the somatodendritic regions of the VTA and SN
may have a lower reserve capacity of DA and, thus, a greater
dependence upon de novo DA biosynthesis in order to maintain
normal DA bioavailability. Conversely, the striatum, which had the
lowest L-DOPA per catecholamine ratio (0.1760.003), may have
the least dependence on de novo DA biosynthesis.
This concept of greater reliance upon de novo DA biosynthesis in
cell body compartments was further supported by a greater degree
of DA turnover in the somatodendritic regions (Fig. 3B). Indeed,
both the SN (0.2060.016) and VTA (0.1860.032) had signifi-
cantly higher DA turnover (pmols DOPAC per pmol DA) than
their cognate terminal fields by 12.5 and 2.8-fold, respectively.
Thus, DA produced in the SN or VTA is more readily catabolized
than DA produced in the striatum or NAc. In conjunction with the
compartmental differences in the ratio of L-DOPA to catechol-
amines, it appears that de novo biosynthesis of DA may have greater
impact on DA bioavailability in the somatodendritic compart-
ments than in the terminal field regions
In vivo relationship of DA and TH phosphorylation
Similar to the aforementioned L-DOPA comparisons, the
relationship of DA tissue content to TH phosphorylation among
the four dopaminergic brain regions was also examined [14,27].
These comparisons were made without NSD-1015 present.
Dopamine tissue content per recovered TH protein was greater
in the terminal field than the somatodendritic regions (Fig. 4A).
Differences in TH phosphorylation at the primary activity-
regulating phosphorylation site should reflect differences in
recovered DA per recovered TH in each region. The relative
phosphorylation of TH among the four regions at both ser31 and
ser40 indicates significantly greater basal ser31 phosphorylation in
both terminal field regions compared to cognate somatodendritic
regions and that ser31, but not ser40, phosphorylation stoichiom-
etry reflected the differences in recovered DA normalized to TH
protein (Figs. 4A, 4B, 4C). Notably, the only phosphorylation site
where the phosphorylation stoichiometry ratios were not signifi-
cantly different from the ratios of DA per TH among the regions
was ser31 (Table 1), suggesting that ser31 phosphorylation plays
an important role in DA regulation in vivo. The differences in TH
protein recovery and relative phosphorylation differences among
the four DA areas examined are illustrated in figure 5.
We note that when comparing ser31 and ser40 phosphorylation
stoichiometries for this set of experiments (Fig. 4B and 4C) to the
previous set of L-DOPA experiments (Fig. 2C and 2D), there is an
apparent affect of NSD-1015 on TH phosphorylation. For
instance, ser40 phosphorylation stoichiometry was 4- to 5-fold
greater in the nigrostriatal pathway following NSD-1015 (Fig. 2D
versus 4C), with no apparent difference in the mesoaccumbens
pathway. Converesely, ser31 phosphorylation stoichiometry was
greater by 2-fold in the mesoaccumbens pathway following NSD-
1015 (Fig. 2C versus 4B), with no apparent difference in the
nigrostriatal pathway. Thus, there appears to be a dichotomous
response between the nigrostriatal and mesoaccumbens pathways
with regard to changes in TH phosphorylation induced by
inhibition of L-DOPA’s conversion into DA by NSD-1015.
ser19 TH phosphorylation in vivo
While phosphorylation of ser19 does not play a direct role in
modulating TH activity [15], it may facilitate ser40 phosphory-
lation [29]. We examined if such a relationship existed in vivo by
conducting correlational analysis of the matched phosphorylation
Figure 3. Increased reliance of cell body regions upon de novo
catecholamine biosynthesis. The ratios of pmols L-DOPA per pmol
catecholamine (DA+NE) and pmols DOPAC per pmol DA (a measure of
DA turnover) were calculated from HPLC analysis of dopaminergic brain
regions dissected from BNF rats (n=4) one hour following i.p.
administration of NSD-1015 (50 mg/kg). A. pmols L-DOPA per pmol
catecholamine, the pmols of L-DOPA recovered from each sample
were divided by the pmols catecholamines recovered within the same
sample.ThemeasurementofcatecholaminesreferstothetotalpmolsDA
combined with pmols NE recovered within a given sample. As L-DOPA
represents a newly synthesized catecholamine precursor, the ratio of
pmols L-DOPA per pmol catecholamine serves as a measure of a region’s
reliance upon de novo catecholamine biosynthesis to maintain adequate
stores. VTA had the greatest L-DOPA per catecholamine ratio (1.160.12)
followed by the SN (0.7560.044) with the striatum (0.1760.003) and NAc
(0.4260.006) having similarly low ratios. Repeated measures ANOVA,
p,0.0001, F=55.4, post-hoc: (***str vs. SN, t=7.35, p,0.001; str vs. NAc,
t=3.24, ns; ***str vs. VTA, t=12.2, p,0.001; *SN vs. NAc, t=4.12, p,0.05;
**SN vs. VTA, t=4.81, p,0.01; ***NAc vs. VTA, t=8.93, p,0.001). B.
pmols DOPAC per pmol DA, the pmols DOPAC (a primary rat
metabolite of DA) from each sample were divided by the pmols DA
recovered within the same sample. This ratio represents a measure of DA
turnover. DA turnover was highest in the SN (0.2060.016) and VTA
(0.1860.032) and significantly less in the NAc (0.06360.0010) and
striatum (0.01660.0003). RepeatedmeasuresANOVA, p,0.0001,F=30.8,
post-hoc: (***str vs. SN, t=8.20, p,0.001; str vs. NAc, t=2.03, ns; ***str vs.
VTA, t=6.99, p,0.001; ***SN vs. NAc, t=6.18, p,0.001; SN vs. VTA,
t=1.22, ns; **NAc vs. VTA, t=4.96, p,0.01).
doi:10.1371/journal.pone.0029867.g003
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ser31 and ser40 phosphorylation stoichiometries. We found a
significant positive correlation between ser19 and ser40 phosphor-
ylation stoichiometry only in the striatum (Fig. 6A). However, in
both somatodendritic compartments, we found a significant
positive correlation between ser19 and ser31 phosphorylation
(Fig. 6B), suggesting that ser19 phosphorylation may influence
ser31 phosphorylation in this compartment.
Compartmental segregation of TH activity:
pharmacological studies
The compartmental segregation of TH activity, as indicated
by basal ser31 TH phosphorylation differences, suggests
autonomy in regulating DA bioavailability in vivo,a n dw e
examined whether this autonomy was maintained following
exogenous compartment-specific reduction of TH activity.
Direct infusion of the TH inhibitor a-methyl-p-tyrosine (AMPT)
(1.4 nmols) into the midbrain produced a consistent and
significant decrease in nigral DA tissue content (90 minutes
later) in comparison to content in the contralateral SN,
averaging ,30% (Fig. 7A), and this was consistently without
effect on DA tissue content in the ipsilateral striatum (Fig. 7A).
The lack of effect of nigral TH inhibition on striatal DA tissue
content was not due to a lack of potency of AMPT in the
striatum, as striatal infusion of AMPT, at the same effective
concentration as in the SN, also reduced striatal DA tissue
Figure 4. Relationship of dopamine tissue content to tyrosine hydroxylase protein and phosphorylation in vivo. DA tissue content and
its relationship to recovered TH protein and phosphorylation shows differences in terminal field and somatodendritic TH activity in the four DA
regions (n=20 for all regions except SN (19)) in BNF rats. Values for pmols DA per mg protein were striatum=842634, SN=3962, NAc=472618, and
VTA=12568. Values for ng TH per mg protein were striatum=343616, SN=9665, NAc=256616, and VTA=179616. A. pmols DA per ng TH
protein in dissected DA neuropil. DA per TH was calculated by dividing the pmols DA per mg protein by the ng TH per mg protein for each
sample. DA per TH was significantly greater in terminal field regions compared to somatodendritic regions. Repeated measures ANOVA,
p,0.0001,F=60.2, post-hoc: (***str vs. SN, t=11.6, p,0.001; str vs. NAc, t=2.74, ns; ***str vs. VTA, t=9.57, p,0.001; ***SN vs. NAc, t=8.83, p,0.001;
SN vs. VTA, t=2.00, ns; ***NAc v. VTA, t=6.83, p,0.001). The pmols DA per ng TH values were str=2.5260.12, SN=0.4260.02, NAc=2.0260.20,
VTA=0.7860.07. B. ser31 phosphorylation stoichiometry. TH phosphorylation stoichiometry at ser31 was significantly higher in the striatum
than all other regions while ser31 phosphorylation stoichiometry was significantly higher in terminal field regions compared to somatodendritic
regions (ANOVA, p,0.0001, F=53.1, post-hoc (***str v. SN, t=11.7, p,0.001; ***str v. NAc, t=5.80, p,0.001; ***str v. VTA, t=9.75; p,0.001; ***SN v.
NAc, t=5.87, p,0.001; ***NAc v. VTA, t=3.95, p,0.001)). Stoichiometry values were str=0.29060.017, SN=0.06960.007, NAc=0.18360.019,
VTA=0.10460.007. These differences reflect the differences in DA per TH observed in Fig 4A. C. ser40 phosphorylation stoichiometry. TH
phosphorylation stoichiometry at ser40 was significantly different between all brain regions except between the striatum and the SN with ser40
phosphorylation being greater in the mesoaccumbens pathway than the nigrostriatal pathway (ANOVA, p,0.0001, F=31.8, post-hoc (***str v. NAc,
t=7.52, p,0.001; **Str v. VTA, t=3.89, p,0.01, ***SN v. NAc, t=8.81, p,0.001; ***SN v. VTA, t=5.19, p,0.001; **NAc v. VTA, t=3.62, p,0.01).
Stoichiometry values were str=0.02560.002, SN=0.01660.002, NAc=0.07060.006, VTA=0.05160.004.
doi:10.1371/journal.pone.0029867.g004
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PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e29867Figure 5. Relative TH protein recoveries and TH phosphorylation stoichiometries in vivo. A. Relative TH protein per total protein.
Standard curve of TH protein ranging from 0.5 to 6.0 ng TH protein used to demonstrate the relative recovery of TH protein in 6 mg total protein from
each of the four regions examined. B. Relative ser
19 TH phosphorylation stoichiometry. Standard curve of calibrated ser
19 phosphorylation
standard, expressed as total ng phosphorylated ser
19, ranging from 0.5 to 6.0 ng, used to demonstrate the relative phosphorylation stoichiometry at
ser
19 among the four regions examined. The somatodendritic compartments of SN and VTA had significantly greater phosphorylation at this site
compared to the cognate terminal field regions in Str and NAc. C. Relative ser
31 TH phosphorylation stoichiometry. Standard curve of
calibrated ser
31 phosphorylation standard, expressed as total ng phosphorylated ser
31, ranging from 0.5 to 7.0 ng, used to demonstrate the relative
phosphorylation stoichiometry at ser
31 among the four regions examined. The somatodendritic compartments of SN and VTA had significantly less
phosphorylation at this site compared to the cognate terminal field regions in Str and NAc. D. Relative ser
40 TH phosphorylation
stoichiometry. Standard curve of calibrated ser
40 phosphorylation standard, expressed as total ng phosphorylated ser
40, ranging from 0.3 to 2.0 ng,
used to demonstrate the relative phosphorylation stoichiometry at ser
40 among the four regions examined.
doi:10.1371/journal.pone.0029867.g005
Table 1. in vivo relationship of DA tissue content to TH phosphorylation.
Region comparison pmols DA perpmol TH ser31 ps ser40 ps* ser19 ps**
Str v. SN 6.13 4.20 1.56 0.18
Str v. NAc 1.25 1.58 0.46 0.50
Str v. VTA 3.20 2.78 0.49 0.10
SN v. NAc 0.20 0.38 0.30 2.78
#
SN v. VTA 0.52 0.66 0.31 0.56
NAc v. VTA 2.57 1.76 1.06 0.20
Legend: The ratio of the described values compare DA per TH and site specific TH phosphorylation stoichiometry (ps) for each possible combination of comparisons in
the four DA brain regions examined. For example, in striatum the pmols DA per pmol TH value is 141 while in the SN this value is 23. Thus, the ratio comparing these
values for Str v. SN is 141/23 or 6.13. There was a significant difference between the six ratios comparing DA per TH versus ser40 and versus ser19 ps, but not ser31 ps.
These data are evidence that under basal conditions, ser31 phosphorylation regulates DA bioavailability within the terminal field and somatodendritic compartments in
vivo. Repeated Measures ANOVA (p=0.0092, F=6.1) followed by Dunnett’s Multiple Comparison Test (DA per TH vs ser31 ps, q=0.82, ns; DA per TH vs. ser40 ps,
q=2.98, *p,0.05; DA per TH vs. ser19 ps, q=3.69, **p,0.01).
#The value for ser19 ps comparing SN v. NAc was excluded from the analysis because it was determined to be a significant outlier by the Grubbs’ test (p,0.01, Z=2.01).
doi:10.1371/journal.pone.0029867.t001
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in the harvested striatal tissue compared with the nigral tissue
(Fig. 1B) [12–14] were not a factor in the lack of effect of nigral
AMPT infusion on striatal DA (Fig. 7A). Furthermore, decreased
striatal DA tissue content following striatal infusion of AMPT did
not produce any effect on nigral DA tissue content (Fig. 7C),
indicating that modulation of TH activity in either compartment
of the nigrostriatal pathway is maintained locally. This finding
also extends to the mesoaccumbens pathway as midbrain
infusion of AMPT similarly reduced DA tissue content in the
VTA without effect on DA tissue content in the nucleus
accumbens (Fig. 8). Taken together, these data demonstrate
that not only is basal regulation of TH segregated between the
somatodendritic and terminal field compartments (as seen in
Fig. 4) but such segregation may be maintained following short-
term pharmacological modulation of TH activity.
Compartmental segregation of TH activity: aging studies
As seen in other aging studies, there was minimal loss of striatal
TH protein (Fig. 9). In the SN, we found a ,25% decrease in TH
protein at 24 months (Fig. 9). There was no significant loss of TH
in either compartment of the mesoaccumbens pathway (Fig. 9).
The long-term process of aging did not uniformly impact TH
phosphorylation in the nigrostriatal pathway. In striatum, there
were no significant overall age-related changes in site-specific
phosphorylation at any TH phosphorylation site (Fig. 10).
However, in the SN, TH phosphorylation decreased at 18 and
24 months compared to 6 months of age at all phosphorylation
sites (Fig. 10).
In the nucleus accumbens, ser19 phosphorylation decreased at
both 18 and 24 months (Fig. 10A), whereas in the VTA, there was
a significant decrease in ser19 at 24 months (Fig. 10A). A similar
disparity of age-related changes in phosphorylation between these
regions was observed at ser31 (Fig. 10B). Notably, no age-related
decrease in ser40 TH phosphorylation was observed in nucleus
accumbens, but there was a significant decrease in ser40
phosphorylation in the VTA at 18 and 24 months (Fig. 10C).
Aging effects on dopamine and metabolites
In our test subjects, there was no evidence of striatal DA loss
with advancing age (Fig. 11). However, in the SN, DA loss of
,20% was observed at 18 and 24 months of age (Fig. 11), which is
consistent with our finding of compartment-specific age-related
reductions in TH phosphorylation. In the mesoaccumbens
pathway, we also found that aging had differential effects on DA
loss. While there was no significant loss of DA in the nucleus
accumbens, there was significant loss in the VTA at both 18 and
24 months (Fig. 11A).
DOPAC, the major rat DA metabolite, followed the pattern of
aging-related DA loss, with no loss in the striatum or nucleus
accumbens but significant age-related loss in the SN and VTA
(data not shown). This result further supports our findings that
there is an overall autonomy in DA regulation between the
somatodendritic and terminal field compartments.
Discussion
Previous work highlighting differences in DA reuptake suggests
a dichotomy in how DA is regulated between cell body and
terminal field regions of the same neuronal pathway. Our work
further supports that such compartmental dichotomies exist in vivo
as evidenced by three major observations: 1) compartmental
differences in TH phosphorylation at ser31 are seen under both
basal conditions and conditions of AADC inhibition, 2) short-term
local inhibition of TH reduces DA only in a targeted compartment
without effect on DA in the cognate compartment of the same
pathway, and 3) the long-term natural process of aging affects DA
and TH phosphorylation in somatodendritic compartments but
not in terminal field compartments.
The differences in L-DOPA (Fig. 1A) and DA ((as per TH)
Fig. 4A) between the somatodendritic and terminal field
compartments of both the nigrostriatal and mesoaccumbens
pathways allowed for an assessment of how ser31 and ser40
phosphorylation may impact DA bioavailability at the biosynthesis
step. Differences in basal ser31, but not ser40, phosphorylation
stoichiometry of TH among the four DA regions examined
matched the differences in DA tissue content (Fig. 4A, 4B, 4C,
Table 1) and also the differences in L-DOPA tissue content
Figure 6. Relationship of ser19 phosphorylation to ser31 and
ser40 phosphorylation in vivo. A. ser19 and ser40 Pearson
correlation analysis shows a significant positive correlation of inherent
ser19 versus ser40 phosphorylation stoichiometries in striatum (Pearson
r=0.54; p=0.014, n=20). Line represents linear regression of data
(y=0.494x+0.006; r
2=0.29). All other regions did not have a significant
correlation between ser19 and ser40 phosphorylation. B. ser19 and
ser31, Midbrain. SN: Pearson correlation analysis shows a significant
positive correlation of inherent ser19 versus ser31 phosphorylation
stoichiometries in SN (Pearson r=0.55; p=0.019, n=18). VTA: Pearson
correlation analysis shows a significant positive correlation of inherent
ser19 versus ser31 phosphorylation stoichiometries in VTA (Pearson
r=0.55; p=0.013, n=20). Combined: Pearson correlation analysis
shows a significant positive correlation of inherent ser19 versus ser31
phosphorylation stoichiometries in SN and VTA (Pearson r=0.67;
p,0.0001, n=38). Line represents linear regression of data
(y=0.17x+0.03; r
2=0.45). No significant relationship of ser19 with
either ser31 or ser40 was observed in the nucleus accumbens.
doi:10.1371/journal.pone.0029867.g006
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PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e29867Figure 7. TH activity is independently regulated in nigrostriatal pathway. A. Nigral TH inhibition decreases DA tissue content
without impact in striatum. AMPT (2.8 nmoles, as methyl ester) was infused unilaterally into the midbrain (coordinates described in methods) of
anesthetized rats. Vehicle was infused in the identical coordinates of the contralateral hemisphere. 90 min following AMPT infusion, the striatum and
SN were dissected, segregating the hemispheres. Tissue was homogenized in HPLC buffer and DA was normalized to total protein content in the
precipitated pellet. Values (mean6SEM) are expressed as pmols DA per mg protein (SN-veh, 4263; SN-AMPT, 2964; Str-ipsiveh, 13446140; Str-ipsi
AMPT, 15036191). Two-tailed Student’s paired t-test was used, comparing AMPT-infused hemisphere versus contralateral vehicle-infused hemisphere
(n=6 rats, **p=0.0036, t=5.17, df=5). B. AMPT, at the effective quantity in SN, also reduces striatal DA tissue content with striatal
infusion. AMPT (2.8 nmoles as methyl ester), at a quantity sufficient to reducenigral DA tissue content (panel A), also significantly decreases striatal
DA tissue content. Values (mean6SEM) are expressed as pmols DA per mg protein (SN-veh, 6965; SN-AMPT, 3762; Str-veh, 19116206; Str-AMPT,
15376108). Two tailed Student’s paired t-test was used, comparing AMPT-infused hemisphere versus contralateral vehicle-infused hemisphere (SN,
n=4 rats, *p=0.033, t=3.7, df=3; Str, n=5 rats, *p=0.043, t=2.9, df=4). C. Striatal TH inhibition decreases DA tissue content locally
without impact in SN. Unilateral AMPT (14 nmoles as methyl ester) infused in striatum significantly decreases striatal DA tissue content without
effect in SN. Values (mean6SEM) are expressed as pmols DA per mg protein (Str-veh, 13606170; Str-AMPT, 1037698; SN-ipsiveh, 4265; SN-ipsi
AMPT, 4065). Two tailed Student’s paired t-test was used, comparing AMPT-infused hemisphere versus contralateral vehicle-infused hemisphere
(n=5 rats, *p=0.019, t=3.8, df=4).
doi:10.1371/journal.pone.0029867.g007
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indicate that under basal conditions, DA tissue content is
influenced by the status of ser31 TH phosphorylation. We do
note, however, that L-DOPA content per recovered TH protein in
the striatum equaled that seen in the SN (Fig. 2A) despite ser31
phosphorylation being greater in striatum (Fig. 2C). VMAT2
protein relative to TH protein content in striatum is 3- to 5-fold
less compared to the other three regions [24], so it is likely that DA
transport into synaptic vesicles is less efficacious in striatum
compared to the other three regions. This would be expected to
lead to increased levels of cytosolic DA in striatum and, in turn,
increased feedback inhibition of TH activity. Thus, we speculate
that the greater ser31 phosphorylation in striatum may be
necessary to overcome the greater DA-mediated inhibition of
TH activity in striatum compared to the other three regions.
The impact of TH activity on DA tissue content in each
compartment of the dopaminergic pathways is also autonomously
maintained within both short- and long-term temporal dynamics
as seen in the AMPT and aging components of this study. Short-
term pharmacological inhibition of TH by AMPT in the
somatodendritic regions decreases DA tissue content therein
without effect in terminal field regions and vice versa. One might
speculate that decreased nigral DA resulting from AMPT infusion
could lead to reduced DA release and subsequently less stimulation
of autoreceptors, thus, enhancing nigrostriatal activity. Indeed,
antipsychotics, which block the action of DA on the autoreceptor,
can increase TH activity and neuronal activity [30], as well as
increase TH phosphorylation within an hour [12], a time frame
similar to our observed AMPT effects. However, the decreases in
DA tissue content following TH inhibition were maintained locally
without effect in cognate compartments, which supports that DA
regulation can be autonomous between somatodendritic and
terminal field regions.
Long-term reduction of TH phosphorylation and DA in the
somatodendritic regions, as seen in aging, is also autonomous, as
aging does not similarly impact terminal field regions. The
compartmental autonomy of TH regulation demonstrated here
has definite implications for the interpretation of behavioral
outcomes influenced by DA release within either compartment of
the nigrostriatal or mesoaccumbens pathways. Our data clearly
indicate that any change in TH protein, TH phosphorylation, or
DA in one compartment does not necessarily reflect similar
changes in the other compartment in either DA pathway.
Significance of site-specific TH phosphorylation in vivo
Our results indicate that ser31 phosphorylation influences TH
activity (from the L-DOPA work) and DA tissue content in vivo.
Previous reports support these results. Even before the discovery of
ser31 as a TH phosphorylation site [4], evidence suggested that a
site other than ser40 played a role in modulating TH activity[31].
Increased ser31 phosphorylation, alone from NGF treatment or in
conjunction with increased ser19 phosphorylation due to depo-
larizing stimulation, enhances L-DOPA accumulation indepen-
dent of ser40 phosphorylation [10,11,32]. A more recent in vivo
study also supports the contention that ser31 regulates basal TH
activity in vivo [14].
However, the premise that ser40 phosphorylation is the
dominant mechanism regulating TH activity still garners wide
acceptance, and many studies measure only ser40 phosphorylation
as an index of TH activity in vivo. While our data do not summarily
dismiss a role for ser40 influencing basal TH activity or DA tissue
content, they do not indicate that ser40 affects DA biosynthesis
under basal conditions. One reason may be that basal ser40
phosphorylation stoichiometry in brain may be less than that
necessary for TH activation and thus, substantial increases above
basal levels may be required to increase L-DOPA biosynthesis. In
Figure 8. Inhibition of TH in VTA is without effect on accumbal
DA tissue content. AMPT (as methyl ester) was unilaterally infused
into the midbrain in anesthetized rat. Vehicle was infused in the
identical coordinates in the contralateral hemisphere. 90 min following
the AMPT infusion, the VTA and core & shell component of nucleus
accumbens (NAc) were dissected, segregating the hemispheres. Tissue
was homogenized in HPLC buffer and DA was normalized to total
protein content in the precipitated pellet. Values (mean6SEM) are
expressed as pmols DA per mg protein (VTA-veh, 8766; VTA-AMPT,
5864; NAc-ipsiveh, 503676; NAc-ipsi AMPT, 535664). Student’s paired
t-test was used, comparing AMPT-infused hemisphere versus contra-
lateral vehicle-infused hemisphere (n=3 rats, *p=0.045, t=4.55, df=2).
doi:10.1371/journal.pone.0029867.g008
Figure 9. Total TH protein as a function of aging. Striatum: (ANOVA, p,0.01, F=9.4, post-hoc: 6 months v 18 months, *p,0.05; 6 months v 24
months, ns; 18 months v 24 months, *p,0.01). Substantia nigra: (ANOVA, *p,0.05, F=5.8, post-hoc: 6 months v. 18 months, ns; 6 months vs. 24
months, ns; 18 months vs. 24 months, *p,0.05). Nucleus Accumbens: (ANOVA, p=0.14, ns). Ventral tegmental area: (ANOVA, p=0.15, ns).
doi:10.1371/journal.pone.0029867.g009
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L-DOPA biosynthesis, but two-fold increases are without effect
[11]. This observation is relevant to in vivo results since basal ser40
phosphorylation levels in PC12 cells or chromaffin cells are ,0.03
[8,11], which is similar to previously reported values in vivo
(,0.02–0.06) [11–14,27]. Therefore, greater than two-fold
increases in ser40 phosphorylation may also be necessary to
increase TH activity in vivo. Thus, pharmacological agents such as
antipsychotics [12,33] or neuropathological events [27,34–37]
may increase ser40 phosphorylation to an extent that would
modulate DA bioavailability. In the mesoaccumbens pathway
where basal ser40 phosphorylation is higher (,0.06, Fig. 4C), it is
possible that less of an increase in ser40 phosphorylation is
required to affect TH activity. As such, ser40 phosphorylation may
Figure 10. Phosphorylation stoichiometry in aging. A. ser19 phosphorylation stoichiometry. Striatum: (ANOVA, p=0.96, ns). Substantia
nigra: (ANOVA, p,0.003, F=11.1, post-hoc: 6 months vs. 18 months, *p,0.05; 6 months vs. 24 months, *p,0.01). Nucleus accumbens: (ANOVA,
p,0.005, F=9.6, post-hoc: 6 months v 18 months, *p,0.01; 6 months v 24 months, *p,0.05). Ventral tegmental area:(ANOVA, p,0.003, F=10.9, post-
hoc: 6 months v 18 months, ns; 6 months v 24 months, *p,0.05). B. ser31phosphorylation stoichiometry. Striatum: (ANOVA, p=0.06, ns).
Substantia nigra: (ANOVA, p,0.004, F=10.0, post-hoc: 6 months vs. 18 months, *p,0.05; 6 months vs. 24 months, *p,0.01). Nucleus accumbens:
(ANOVA, p,0.03, F=5.3, post-hoc: 6 months v 18 months, *p,0.05; 6 months v 24 months, ns). Ventral tegmental area: (ANOVA, p,0.01, F=7.6, post-
hoc: 6 months v 18 months, ns; 6 months v 24 months,ns; 18 months v 24 months, *p,0.01). C. ser40phosphorylation stoichiometry. Striatum:
(ANOVA, p=0.27, ns). Substantia nigra: (ANOVA, p,0.01, F=8.8, post-hoc: 6 months vs. 18 months, *p,0.01; 6 months vs. 24 months, *p,0.05.
Nucleus accumbens: ANOVA, p=0.51, ns. Ventral tegmental area: (ANOVA, p,0.004, F=10.2, post-hoc: 6 months v 18 months, *p,0.05; 6 months v
24 months,*p,0.01).
doi:10.1371/journal.pone.0029867.g010
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pathway. Thus, the age-related decrease in ser40 in the VTA
(Fig. 10C), could be at least partially responsible for the loss of DA
at 18 and 24 months (Fig. 11A).The existence of two phosphor-
ylation sites, which affect TH activity, could represent two distinct
mechanisms of controlling TH activity. Our data suggest that
ser31 phosphorylation likely regulates TH under most neurobio-
logical ‘‘backgrounds’’ but that ser40 could play more of a role in
the mesoaccumbens pathway or under extraordinary events
associated with elevated DA signaling in vivo. A thorough
investigation could determine how much change in phosphoryla-
tion at ser31 versus ser40 is required to affect L-DOPA
biosynthesis in vivo.
A potentially novel relationship between ser19 and ser31
phosphorylation in the somatodendritic regions (Fig. 6B) may
point to mechanisms of DA replenishment. Depolarization-
stimulated catecholamine release activates TH [38] via Ca
2+-
dependent increases in TH phosphorylation [11,39]. Medial
forebrain bundle stimulation increases TH phosphorylation, and
in striatal synaptosomes, depolarizing-stimuli increase ser19
phosphorylation first, followed by increased ser31 phosphorylation
with no effect on ser40 phosphorylation [9]. Thus, the positive
correlation of ser19 phosphorylation with ser31 phosphorylation in
the SN and VTA suggests that ser19 could be responsive to DA
neuron activity and may facilitate ser31 phosphorylation in order
to increase L-DOPA biosynthesis. The parallel aging-related
decreases in phosphorylation at these two sites in SN and VTA
(Fig. 10A, 10B) also support this possibility. Although ser19 does
not directly influence TH activity [15,29], it facilitates ser40
phosphorylation in situ [29]. We also observed a significant positive
correlation between ser19 and ser40 phosphorylation in striatum
(Fig. 6A). The relationship of ser19 and ser31 phosphorylation in
the somatodendritic regions makes a compelling case that ser19
phosphorylation may also facilitate ser31 phosphorylation.
The significance of dichotomous DA regulation in vivo
Our results have illustrated the significant impact of TH protein
and TH activity on DA bioavailability and illuminated how TH
activity could be comparatively more critical for maintaining DA
in the somatodendritic regions. Following AADC inhibition by
Figure 11. Dopamine tissue content in aging. Both bar graph (A) and individual points with line designating group mean (B) are shown to
demonstrate the individual test subject variance in relation to the mean in the nigrostriatal pathway. Striatum: (ANOVA, p=0.62, ns). Substantia nigra:
(ANOVA, p=0.0017, F=12.9, post-hoc: 6 months vs. 18 months, *p,0.01; 6 months vs. 24 months, *p,0.01). Nucleus accumbens: (ANOVA, p=0.08,
ns). Ventral tegmental area: (ANOVA, p,0.0001, F=27.8, post-hoc: 6 months v 18 months, *p,0.001, 6 months v 24 months, *p,0.001).
doi:10.1371/journal.pone.0029867.g011
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the somatodendritic compartments, indicating much less DA
reserve therein (Fig. 3A). There was also much greater DA
turnover in the somatodendritic compartments (Fig. 3B). Others
have reported far less DA reuptake capacity in the somatodendritic
regions [17–22], likely due to much less DAT per TH compared to
terminal fields [24]. Together, these observations suggest that TH
activity is perhaps the most critical determinant of DA
bioavailability for release in the somatodendritic regions. Yet,
given these tremendous constraints, ser31 phosphorylation is
surprisingly less in cell body regions than in the terminal fields
(Fig. 2B, 4B). One possible reason for this may be differences in the
expression of a regulatory subunit of protein phosphatase 2A [40],
which can dephosphorylate ser31. It is present in the SN, but
notably absent in striatum. This difference in phosphatase
expression would result in greater TH dephosphorylation in the
SN compared to striatum.
This distinct difference in how TH may regulate DA between
striatum and SN may be of significant consequence in models of
Parkinson’s disease [41,42] and aging [14,43], wherein locomotor
dysfunction may be related to deficient DA regulation. Our results
show that TH phosphorylation and DA levels in the somatoden-
dritic regions are particularly vulnerable to aging, with loss of each
occurring between 6 and 18 months in the SN. In the VTA, loss of
DA was also seen between 6 and 18 months. However, we
previously reported no difference in VTA DA between 12 and 30
months [14], so loss of DA in this brain region likely takes place
between 6 and 12 months. In the nigrostriatal pathway, this
dichotomy in TH regulation with aging may be related to a nigra-
specific decline in the expression of a major extracellular regulator
of TH, the soluble GFR a-1 receptor [44].
Effects of somatodendritic DA regulation on behavior
If TH activity in the somatodendritic region is a critical
regulatory component of DA bioavailability therein, it stands to
reason that alterations in TH activity would significantly influence
DA signaling in SN and VTA and, hence, behaviors affected by
DA signaling in these regions. Somatodendritic release of DA is
well established [45] and distinct from terminal fields in the
quantity of DA released and dynamics of DA reuptake [17,18,22].
In intact DA neuropil of pharmacologically-naı ¨ve rats, nigral, but
not striatal, DA tissue content and ser31 TH phosphorylation
positively correlate to movement initiation capacity [14]. Further-
more, pharmacological interventions specifically targeting nigral
DA signaling affect locomotor activity [46–50]. The importance of
somatodendritic DA release is also relevant to the mesoaccumbens
pathway where the process of drug reinforcement may be
influenced by increased DA tone in VTA [51], which appears to
be mediated, in part, by growth factor signaling specifically in the
VTA [52–54]. Growth factor-mediated effects on nigrostriatal and
mesoaccumbens pathways are derived from retrograde signaling
originating in terminal field regions but ultimately affect
somatodendritic DA function [13,54–57]. In fact, growth factor-
mediated improvement in locomotor capabilities in models of
Parkinson’s disease and aging can occur with increased TH
expression, TH phosphorylation, or DA tissue content strictly in
the SN [13,58–60]. Thus, selective modulation of TH activity
strictly in the somatodendritic regions of SN or VTA could have
significant consequences for behaviors modulated by DA.
In summary, our findings support the idea that TH activity, as
regulated by ser31 phosphorylation, contributes to autonomous
regulation of DA between the somatodendritic and terminal field
compartments of the nigrostriatal and mesoaccumbens pathways.
In particular, TH activity may be more important to the
maintenance of DA bioavailability in somatodendritic regions as
previously demonstrated by less DA reuptake and DAT protein
expression and, as revealed here, by a greater L-DOPA per
catecholamine ratio and higher DA turnover. This dichotomy of
TH regulation is further supported by the compartment-specific
loss of DA following local inhibition of TH activity and the specific
loss of DA and TH phosphorylation only in somatodendritic
regions during the natural process of aging. These results shed a
new light on the importance of the significance of the
neuroanatomical loci of TH measures and how the autonomy of
DA and TH regulation between somatodendritic and terminal
field regions may contribute to behavioral outcomes.
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